Participant flow

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · Source last updated 2011-11-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.

   id

   FG000

   title

   Bortezomib; Docetaxel

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         18

      type

      Progression of disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Twenty-seven patients consented, two of which were ineligible.

recruitment Details

This study was open to accrual from 8/25/2005 through 5/20/2008.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice